Skip to main content
Home
Home

Jonathan S. Schulman

Profile photo for Jonathan S. Schulman
Profile photo for Jonathan S. Schulman
Partner

Jonathan S. Schulman

Jonathan provides experienced advice to clients engaged in sophisticated capital markets transactions and corporate governance matters.

Jonathan Schulman advises public companies in capital markets transactions and in connection with their U.S. Securities and Exchange Commission (SEC) disclosure obligations and related corporate governance matters.

Jonathan represents clients in a variety of capital markets transactions, including initial public offerings, underwritten equity and debt offerings, Rule 144A debt offerings, convertible note offerings, and private placements. Jonathan serves as a trusted advisor to public companies on SEC reporting, compliance and disclosure issues, stock exchange rules, and general corporate matters. Jonathan also represents public companies in mergers and acquisitions.

Education & Credentials

Education

  • University of Virginia School of Law, J.D., Editorial Board, Virginia Law & Business Review, 2014
  • University of Miami, B.B.A., Entrepreneurship, summa cum laude, 2010

Bar and Court Admissions

  • Colorado
  • New York

Related Employment

  • Latham & Watkins LLP, New York, NY and Washington, D.C., Associate, 2014-2018
  • Latham & Watkins LLP, New York, NY, Summer Associate, 2013

Professional Recognition

  • Recognized by Best Lawyers: Ones to Watch for Corporate Law, 2024

Professional Experience

Capital Markets & Corporate Finance

Crocs

Represented Crocs in multiple Rule 144A senior notes offerings.

Crocs

Represented Crocs in a block trade of its common stock.

Amcor

Represented Amcor in multiple senior notes offerings.

Gevo

Represented Gevo in multiple follow-on common stock and warrant offerings.

CAI International

Represented CAI International in multiple preferred stock offerings.

Ideal Power

Represented Ideal Power in multiple follow-on offerings.

Fate Therapeutics

Represented the underwriters in multiple follow-on offerings of Fate Therapeutics.

Other Offerings

Representation of other various issuers and underwriters in connection with initial public offerings, underwritten public offerings, private investment in public equity (PIPEs), private placements and other financing transactions.

Mergers & Acquisitions

Crocs

Represented Crocs (Nasdaq: CROX) in its $2.5 billion acquisition of HEYDUDE.

Pacira BioSciences

Represented Pacira BioSciences (Nasdaq: PCRX) in its acquisition of Flexion Therapeutics (Nasdaq: FLXN).

CAI International

Represented CAI International (NYSE: CAI) in its acquisition by Mitsubishi HC Capital.

Pacira BioSciences

Represented Pacira BioSciences (Nasdaq: PCRX) in its acquisition of MyoScience.

SMTC Corporation

Represented SMTC Corporation (Nasdaq: SMTX) in its acquisition by H.I.G. Capital.

AeroGrow

Represented AeroGrow (OTC: AERO) in its acquisition by Scotts Miracle-Gro (NYSE: SMG).

Peak Resorts

Represented Peak Resorts (Nasdaq: SKIS) in its acquisition by Vail Resorts (NYSE: MTN).

Home
Jump back to top